NCT06137274RecruitingPhase 2
Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC
Phase 2 Trial of Adaptive Radiotherapy Boost for Head and Neck Squamous Cell Carcinomas
Source: ClinicalTrials.gov · Last updated 1 Apr 2026
Brief summary (registry, in English)
The purpose of the study is to determine if it is feasible to use magnetic resonance imaging (MRI) to adjust a portion of radiation therapy for patients with head and neck squamous cell carcinoma . The technique under study will be used to personalize the study treatment based on response, keeping all treatments within standard of care guidelines.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 13 Nov 2023
- Start date
- 14 Dec 2023
- Primary completion date
- 31 May 2027
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Diseases
- Head and neck cancer
- NCT number
- NCT06137274
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 35
- From 14 Dec 2023 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have had prior radiotherapy to the head and neck or prior systemic therapy for the index cancer.
Other illness
- Patients who had undergone definitive surgery for the index cancer.
- Patients with distant metastatic disease
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
Other
- Pregnancy or lactation
Who the study is looking for
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- ECOG performance status of 0, 1
- Patients with histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or unknown primary in the neck.
- Patients with measurable disease, either at primary site or neck per RECIST 1.1.
- For patients planned to receive chemotherapy, adequate hematologic, hepatic and renal function as outlined in protocol.
- International normalized ratio of prothrombin time (INR) and prothrombin time (PT) within 28 days before randomization must be WNL for the lab. Patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history.
- Negative serum pregnancy test within before starting study treatment in woman with childbearing potential.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Moffitt Cancer Center Coordinator of this site? Confirm its status | Tampa | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.